New hope for stubborn arthritis: drug trial targets unresponsive cases
NCT ID NCT06625242
Summary
This study is testing how well the drug filgotinib works and how safe it is for Korean adults with rheumatoid arthritis who haven't gotten enough relief from other standard medications. About 118 participants will take filgotinib for 24 weeks, and researchers will measure improvements in arthritis symptoms and joint pain. The main goal is to see how many patients experience a meaningful 20% improvement in their symptoms after 12 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai site #01
Busan, South Korea
-
Eisai site #02
Gwangju, South Korea
-
Eisai site #03
Seoul, South Korea
-
Eisai site #04
Seoul, South Korea
-
Eisai site #05
Seoul, South Korea
-
Eisai site #06
Daejeon, South Korea
-
Eisai site #07
Seoul, South Korea
-
Eisai site #08
Seoul, South Korea
-
Eisai site #09
Daegu, South Korea
-
Eisai site #10
Seoul, South Korea
-
Eisai site #11
Anyang-si, South Korea
-
Eisai site #12
Daegu, South Korea
-
Eisai site #13
Incheon, South Korea
-
Eisai site #14
Seoul, South Korea
-
Eisai site #15
Guri-si, South Korea
Conditions
Explore the condition pages connected to this study.